Arecor to participate At PEPTalk 2020’s Protein Science Week In San Diego, CA, USA

Cambridge, UK., 16 January 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces Dr Jan Jezek, Chief Scientific Officer, will present at PEPTalk 2020, in San Diego, California, USA on 20-24 January 2020.

Dr. Jezek’s PEPTalk presentation, entitled ‘Controlling Aggregation of a Range of Novel Biopharmaceutical Product Modalities’, will summarise several case studies demonstrating the capability of Arecor’s formulation technology platform, Arestat™, to develop differentiated biopharmaceutical products and explain some of the key scientific principles that underpin this technology.

Date: Friday, 24 January 2020
Time: 10:05-10:35
Session: Protein Aggregation and Emerging Analytical Tools
Location: Hilton San Diego Bayfront, San Diego, CA

Aggregation is one of the main technical hurdles in developing high-value biopharmaceutical products. This is particularly the case with a number of novel product constructs, including bispecific antibodies, antibody fragments or viral vectors used in gene therapy. Aggregated products may result in undesirable immune response or they may affect the therapeutic efficacy. Therefore, the level of aggregation in biopharmaceutical compositions must be maintained to a minimum. Arecor has developed a proprietary formulation technology, Arestat™, that enables superior biopharmaceutical products via minimising the rate of aggregation as well as other degradation pathways. Application of the technology allows development of safe and convenient products that would otherwise not be achievable using conventional approaches to formulation.


For more information, please contact:
Arecor Limited

Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060

Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060

Notes to Editors

About Arecor (
Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

For further details please see our website,

Media Contact Information: 

Mo PR Advisory

Mo Noonan Mob: +44 (0) 7876 444977